Melanoma sensitivity

Del Mistro, G., S. Riemann, S. Schindler, S. Beissert, R. E. Kontermann, A. Ginolhac, R. Halder, L. Presta, L. Sinkkonen, T. Sauter and D. Kulms (2022). "Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma." Cell Death & Disease 13(1): 54. Melanoma Sensitivity doi.org/10.1038/s41419-022-04502-8.

Müller, I., E. Strozyk, S. Schindler, S. Beissert, H. Z. Oo, T. Sauter, P. Lucarelli, S. Raeth, A. Hausser, N. Al Nakouzi, L. Fazli, M. E. Gleave, H. Liu, H.-U. Simon, H. Walczak, D. R. Green, J. Bartek, M. Daugaard, and D. Kulms (2020). "Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28." Molecular Cell. www.sciencedirect.com/science/article/pii/S1097276519309530.

Rozanc, J., Sakellaropoulos, T., Antoranz, A., Gutta, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., Kulms, D., Rehm, M. and Alexopoulos, L. G. (2019). "Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma." Cell Death Differ 26(8): 1365-1378. www.ncbi.nlm.nih.gov/pubmed/30323272.

Del Mistro, G., Lucarelli, P., Muller, I., De Landtsheer, S., Zinoveva, A., Hutt, M., Siegemund, M., Kontermann, R. E., Beissert, S., Sauter, T. and Kulms, D. (2018). "Systemic network analysis identifies XIAP and IkappaBalpha as potential drug targets in TRAIL resistant BRAF mutated melanoma." NPJ Syst Biol Appl 4: 39. www.ncbi.nlm.nih.gov/pubmed/30416750.

Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C. and Meier, F. (2018). "Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy." Pharmacological Research 136: 151-159. www.ncbi.nlm.nih.gov/pubmed/30145328.

Müller, I. and Kulms, D. (2018). "A 3D Organotypic Melanoma Spheroid Skin Model." Journal of Visualized Experiments: JoVE(135). www.ncbi.nlm.nih.gov/pubmed/29863656.

Rozanc, J., Sakellaropoulos, T., Antoranz, A., Gutta, C., Podder, B., Vetma, V., Rufo, N., Agostinis, P., Pliaka, V., Sauter, T., Kulms, D., Rehm, M. and Alexopoulos, L. G. (2018). "Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma." Cell Death Differ. www.ncbi.nlm.nih.gov/pubmed/30323272.

Siegemund, M., Schneider, F., Hutt, M., Seifert, O., Müller, I., Kulms, D., Pfizenmaier, K. and Kontermann, R. E. (2018). "IgG-single-chain TRAIL fusion proteins for tumour therapy." Scientific Reports 8(1): 7808. www.ncbi.nlm.nih.gov/pubmed/29773864.

De Landtsheer, S., Trairatphisan, P., Lucarelli, P., Sauter, T., 2017. FALCON: a toolbox for the fast contextualization of logical networks. Bioinformatics 33, 3431–3436. doi.org/10.1093/bioinformatics/btx380

Hutt, M., Marquardt, L., Seifert, O., Siegemund, M., Müller, I., Kulms, D., Pfizenmaier, K., Kontermann, R.E., 2017. Superior Properties of Fc-comprising scTRAIL Fusion Proteins. Mol. Cancer Ther. 16, 2792–2802. doi.org/10.1158/1535-7163.MCT-17-0551

Niessner, H., Sinnberg, T., Kosnopfel, C., Smalley, K.S.M., Beck, D., Praetorius, C., Mai, M., Beissert, S., Kulms, D., Schaller, M., Garbe, C., Flaherty, K.T., Westphal, D., Wanke, I., Meier, F., 2017. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. Clin. Cancer Res. 23, 6203–6214. doi.org/10.1158/1078-0432.CCR-17-0098

Albrecht, M., Sciumè, G., Lucarelli, P., Sauter, T., 2016. Thermodynamically constrained averaging theory for cancer growth modelling*. IFAC-PapersOnLine, Foundations of Systems Biology in Engineering - FOSBE 2016Magdeburg, Germany, 9—12 October 2016 49, 289–294. doi.org/10.1016/j.ifacol.2016.12.141

Niessner, H., Schmitz, J., Tabatabai, G., Schmid, A.M., Calaminus, C., Sinnberg, T., Weide, B., Eigentler, T.K., Garbe, C., Schittek, B., Quintanilla-Fend, L., Bender, B., Mai, M., Praetorius, C., Beissert, S., Schackert, G., Muders, M.H., Meinhardt, M., Baretton, G.B., Dummer, R., Flaherty, K., Pichler, B.J., Kulms, D., Westphal, D., Meier, F., 2016. PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo. Clin. Cancer Res. 22, 5818–5828. doi.org/10.1158/1078-0432.CCR-16-0064